Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.
Dinetz. Elliot E; Lee. Edwin E
Key Findings
- Safety and tolerability were confirmed across thousands of participants
- Evidence of benefit in COVID‑19, autoimmune disorders, and cancer treatment
- The authors argue the FDA’s 2023 restriction on thymosin‑alpha‑1 is not supported by the data
Practical Outcomes
- For DIY health enthusiasts, thymosin‑alpha‑1 appears to be a well‑tolerated immune modulator, so it could be considered as a supplement under medical guidance. If legal in your area, compounding pharmacies may be a source, but you’ll still need to determine dosing and monitor effects yourself.
Summary
A big review of over 11,000 people in more than 30 trials found that thymosin‑alpha‑1 is generally safe and can help the immune system in illnesses like COVID‑19, autoimmune diseases, and some cancers, challenging recent FDA limits on the peptide.
Abstract
This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Tα1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials. The focus was on Tα1's application in COVID-19, autoimmune conditions, and cancer treatment, with implications for future considerations. We systematically searched articles relevant to critical studies on COVID-19, infectious diseases, cancer, and autoimmune diseases indexed on Pubmed, Google Scholar, and Cochrane Library. Our focus was on evaluating the safety and efficacy of Tα1 in human subjects. Clinical trials conducted worldwide involving diverse populations were analyzed to assess the safety and effectiveness of Tα1. The review examines explicit outcomes in over 11 000 human subjects, emphasizing its role in addressing COVID-19, autoimmune conditions, and cancer treatment. Contrary to the FDA's restriction on Tα1 and 21 additional peptides in 2023, our analysis reveals consistent evidence of Tα1's safety and efficacy. The peptide has demonstrated significant effectiveness in treating various conditions, including COVID-19, autoimmune disorders, and cancer. This review summarizes conclusions drawn from a comprehensive examination of clinical trials worldwide. Based on substantial evidence from clinical trials, Tα1 emerges as a well-tolerated and effective immune modulator. The FDA›s restriction appears unfounded, as Tα1 has shown safety and efficacy beyond the initially specified conditions. Urgent attention and intervention are warranted to ensure the continued availability of this life-saving peptide through prescription. Therefore, it is recommended that the FDA permits 503A compounding pharmacies to compound Tα1, considering its potential to treat a variety of conditions effectively.
Study Information
pubmed
2024